pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Hezkue
drug · small molecule
save

sildenafil citrate

Phase 2updated 6mo ago
by $DARE Dare Bioscience, Inc.🔗 ChEMBL
Phase 2
community read0 votes

🐶 often sniffed alongside

top 7
  • drugVYBRIQUE2 co-mentions · 1 sources
  • tagApproval2 co-mentions · 1 sources
  • drugViagra1 co-mentions · 1 sources
  • drugASP-001.11 co-mentions · 1 sources
  • tagSmall Molecule1 co-mentions · 1 sources
  • drugRevatio1 co-mentions · 1 sources
  • drugsildenafil citrate SR1 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 30 investigational indications.

targets

cGMP-specific 3',5'-cyclic phosphodiesterase

all catalysts(0)

nothing on the calendar yet

Trials studying sildenafil citrate

  • phase1PK and Onset of Hezkue Oral Sildenafil Suspension After Alcohol Consumptionnot yet recruitingn=24
  • phase2Effect of Moderate Alcohol on Absorption and Onset of Hezkue Sildenafil Suspensionnot yet recruitingn=36
  • phase2Phase 2 Efficacy Study of Sildenafil Products in Adult Men With Erectile Dysfunctionnot yet recruitingn=200

News(10)

  • #CTAD26: AriBio’s repurposing of ED drug for Alzheimer’s yields tepid results
    BOSTON — For years, scientists have wondered whether Viagra-like pills could have an unexpected benefit in the brain. Some real-world evidence suggests men who take erectile dysfunction medicines a…
    endpoints · 15h ago
  • Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera asset
    With 10 active or planned Phase 3 trials underway for Metsera’s berobenatide, Pfizer has signed a deal with Blackstone Life Sciences to finance the program to approval.
    biospace · 4d ago
  • With MFN now embedded in pharma, execs see little impact from Democrats’ blue wave
    Speaking on third quarter earnings calls this week, Novo and Pfizer’s CEOs see little change to their Most Favored Nation drug pricing deals, which were signed with the Trump administration last year.
    biospace · 13d ago
  • Pfizer eyes Europe first for Lyme vaccine as prevalence rises in US
    Since Pfizer already owns a tick-borne encephalitis franchise in Europe, the region is a natural first step for the pharma’s upcoming Lyme disease vaccine.
    biospace · 13d ago
  • Pfizer, fresh to China’s obesity market, looks to Viagra model to compete
    Pfizer is calling upon lessons learned from one of the first drugs ever made available on the internet—Viagra—as it commercializes a new obesity drug in China.
    biospace · 13d ago
  • Tonight We Ride, LLC Issues Voluntary Recall of Ultimate Forza Male Supplement Due to Presence of Undeclared Sildenafil, Tadalafil, and Dapoxetine
    October 24, 2026, Tonight We Ride, LLC of Lakeville, Minnesota is voluntarily recalling all lots of Ultimate Forza Male Supplement capsules to the consumer level because it has been found to contai…
    fda_recalls · 23d ago
  • Lilly-backed TRex rakes in $117M IPO, while hypertension biotech Retension reveals $45M listing
    Eli Lilly-backed TRex Bio and hypertension-focused Retension Pharmaceuticals brought in $116.7 million and $45 million from their respective IPOs, continuing a bumper year for biotech listings.
    fiercebiotech · 1mo ago
  • TRex Bio stomps toward $111M IPO, as Retension and Lycia also gear up to go public
    Eli Lilly-backed TRex Bio is aiming for a $111.3 million IPO, while hypertension-focused Retension Pharmaceuticals hopes for a more modest $33.8 million and protein degradation biotech Lycia Therap…
    fiercebiotech · 1mo ago
  • Retension and Lilly-backed TRex Bio both set out plans to join biotech IPO stampede
    Eli Lilly-backed TRex Bio and hypertension-focused Retension Pharmaceuticals are the latest biotechs to set out plans to go public this year.
    fiercebiotech · 1mo ago
  • A&P Creations LLC Issues Nationwide Recall of biQ-FEL Due to Undeclared Sildenafil and Tadalafil
    Sildenafil and Tadalafil are active ingredients in FDA-approved prescription drugs Viagra and Cialis, respectively, used to treat erectile dysfunction. FDA approval of Viagra and Cialis is restrict…
    fda_recalls · 2mo ago
view all news mentions →
brand
Hezkue
trade names
Granpidam, Liqrev, Mysildecard, Nipatra, Patrex, Revatio
generic
sildenafil citrate
MOA
Phosphodiesterase 5A inhibitor
indication
Female Hypoactive Sexual Desire Disorder
phase
phase_2
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 36m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?